BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $95.00 at Truist Financial

BridgeBio Pharma (NASDAQ:BBIO) had its price objective upped by equities research analysts at Truist Financial from $86.00 to $95.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s target price points to a potential upside of 44.67% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a research report on Wednesday, January 21st. Raymond James Financial set a $89.00 target price on BridgeBio Pharma and gave the stock an “outperform” rating in a report on Thursday, February 12th. Oppenheimer boosted their price target on BridgeBio Pharma from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Piper Sandler increased their price objective on BridgeBio Pharma from $93.00 to $98.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. Finally, Barclays initiated coverage on BridgeBio Pharma in a research report on Wednesday, January 28th. They issued an “overweight” rating on the stock. Twenty-two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $82.50.

BridgeBio Pharma Trading Down 3.9%

Shares of BBIO traded down $2.65 during trading hours on Wednesday, hitting $65.67. 2,480,744 shares of the stock traded hands, compared to its average volume of 3,267,873. The business has a fifty day moving average of $75.24 and a 200-day moving average of $64.53. The firm has a market capitalization of $12.65 billion, a PE ratio of -15.75 and a beta of 1.13. BridgeBio Pharma has a 1-year low of $28.33 and a 1-year high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The firm had revenue of $154.18 million during the quarter, compared to the consensus estimate of $150.71 million. During the same quarter in the prior year, the business posted ($1.40) earnings per share. The firm’s revenue for the quarter was up 2521.2% compared to the same quarter last year. As a group, equities research analysts expect that BridgeBio Pharma will post -3.67 earnings per share for the current fiscal year.

Insider Buying and Selling at BridgeBio Pharma

In related news, CFO Thomas Trimarchi sold 13,600 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the transaction, the chief financial officer directly owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $74.26, for a total transaction of $148,520.00. Following the completion of the sale, the chief accounting officer directly owned 130,297 shares of the company’s stock, valued at $9,675,855.22. This represents a 1.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 204,174 shares of company stock valued at $15,012,335. 18.20% of the stock is currently owned by insiders.

Institutional Trading of BridgeBio Pharma

Large investors have recently made changes to their positions in the company. Corient Private Wealth LLC bought a new stake in shares of BridgeBio Pharma during the 2nd quarter worth $643,000. WINTON GROUP Ltd bought a new position in shares of BridgeBio Pharma in the 2nd quarter valued at $3,856,000. Principal Financial Group Inc. lifted its stake in shares of BridgeBio Pharma by 23.0% in the 3rd quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock valued at $65,829,000 after acquiring an additional 236,885 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of BridgeBio Pharma by 53.0% during the 3rd quarter. Federated Hermes Inc. now owns 424,695 shares of the company’s stock valued at $22,059,000 after acquiring an additional 147,108 shares in the last quarter. Finally, L & S Advisors Inc acquired a new stake in shares of BridgeBio Pharma during the 3rd quarter valued at $877,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Morgan Stanley raised its price target to $98 and kept an “overweight” rating, implying roughly ~47% upside vs. the current price — a clear buy-side signal that can support the stock. Benzinga
• Positive Sentiment: BridgeBio reported Q4 revenue of $154.2M vs. ~$150.7M expected and revenue was up ~2,521% year‑over‑year — evidence of commercial traction (Attruby was highlighted in the company release), which reduces near‑term execution risk. GlobeNewswire
• Positive Sentiment: Several Wall Street shops have been raising targets recently (Cantor Fitzgerald, HC Wainwright, Goldman and others noted), which can attract momentum buyers and support higher valuations. MarketBeat analyst roundup
• Neutral Sentiment: Full Q4 earnings call/transcripts are available — useful for details on Attruby uptake, guidance and pipeline timelines; these may provide follow‑up catalysts but are informational until new guidance or data appear. Yahoo Finance transcript
• Negative Sentiment: BridgeBio missed on EPS: reported a ($1.00) loss vs. ($0.75) expected — the wider-than-expected loss is pressuring near-term sentiment despite the revenue beat. Zacks
• Negative Sentiment: CEO Neil Kumar sold 28,053 shares (recently part of several sales), a sizable insider disposition that can raise short-term investor caution even if filings show he retains a large stake. InsiderTrades / SEC filing

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.